XP Inc. initiated with a Neutral at BTG Pactual » 08:1301/2701/27/20
BTG Pactual initiated…
BTG Pactual initiated coverage of XP Inc. with a Neutral rating and $37 price target.
Ten new option listings and two option delistings on January 23rd » 08:3001/2301/23/20
AKRO, AQST, CYCN, ITRN, OBSV, PHAS, PHAT, STOK, XP, MDR, TOO
New option listings for…
New option listings for January 23rd include Akero Therapeutics Inc (AKRO), Aquestive Therapeutics Inc (AQST), Cyclerion Therapeutics Inc (CYCN), Ituran (ITRN), McDermott International Inc (MDRIQ), ObsEva (OBSV), PhaseBio Pharmaceuticals Inc (PHAS), Phathom Pharmaceuticals Inc (PHAT), Stoke Therapeutics Inc (STOK), and XP Inc (Class A Stock) (XP). Option delistings effective January 23rd include McDermott International Inc (MDR) and Teekay Offshore Partners LP (Units) (TOO).
|Over a week ago|
Morgan Stanley starts XP Inc. at Overweight with $45 price target » 09:5501/0601/06/20
Morgan Stanley analyst…
Morgan Stanley analyst Jorge Kuri initiated coverage of XP Inc. with an Overweight rating and $45 price target, citing his view that the company is well positioned to capture strong industry growth and asset allocation shifts in Brazil given its "best-in-class" technology, superior open platform, leading IFA distribution network, brand name and execution. XP is the largest online broker in Brazil "by far" and it offers consumers a variety and depth of product and a level of advisory and service that the incumbent banks don't, Kuri tells investors.
XP Inc. initiated with an Overweight at Morgan Stanley » 09:2801/0601/06/20
Morgan Stanley initiated…
Morgan Stanley initiated coverage of XP Inc. with an Overweight rating and $45 price target.
XP Inc. initiated with an Overweight at JPMorgan » 08:5901/0601/06/20
JPMorgan analyst Domingos…
JPMorgan analyst Domingos Falavina initiated coverage of XP Inc. with an Overweight rating and $44 price target. The company is "rapidly" growing as clients move away from traditional banks to independent investment advisors, Falavina tells investors in a research note. Hisanalysis indicates that XP offers the broadest range of investment alternatives to its clients at more competitive price.
XP Inc. initiated with a Neutral at Goldman Sachs » 21:5301/0501/05/20
Goldman Sachs analyst…
Goldman Sachs analyst Tito Labarta initiated coverage of XP Inc. with a Neutral rating and $40 price target. The analyst thinks XP is "uniquely positioned" to gain share from the large banks in Brazil as an independent Brazilian financial advisor. However, he views the stock's current valuation as "rich."
|Over a month ago|
Opening Day: XP finishes first week higher, Sprout Social lower » 15:2512/1512/15/19
BILL, EH, HCCO, OCFT, SPT, XP
This past week saw six…
XP opens at $32.75, IPO priced at $27.00 per share 11:4112/1112/11/19
XP indicated to open at $32.50, IPO priced at $27.00 11:2912/1112/11/19
XP indicated to open at $32.00, IPO priced at $27.00 10:5312/1112/11/19